Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450070 · ClinicalTrials.gov registry record · NA
Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
A NA study of Allergic Sensitization, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
- 1
- Study location
NCT03450070: Completed NA study of Allergic Sensitization, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
NCT03450070 is a NA study of Allergic Sensitization that has completed, run by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies. The registered enrollment target is 121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03450070, a NA study of Allergic Sensitization, has completed, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
Patch Testing for device cream on human subjects
Primary Outcome
"Clinically Significant Dermal Irritation" refers to an overall outcome measure in which, after 6 weeks of the test (patching the skin (3 weeks) \& then challenging the skin (at week 6)), the test product caused a clinically significant dermal reaction (scores of 2 or greater). Participant scores less than 2 are not considered to be Clinically significant. Scoring System: 0 = No visible reaction ± = Faint, minimal erythema 1. = Erythema 2. = Intense erythema 3. = Intense erythema, induration
Conditions Studied
Interventions
- DEVICE Light Therapy Mask Cream
Study Locations (1)
New Jersey
- Harrison Research Laboratories - Union
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2017-12-22 |
| Phase | NA |
Sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies4 total trials
What the finished NCT03450070 record still lists
NCT03450070 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Allergic Sensitization appearing as the primary indexed condition, and to 1 intervention - of which Light Therapy Mask Cream is the first listed.
NCT03450070 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03450070 about?
NCT03450070 is a clinical study titled "Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100". Patch Testing for device cream on human subjects
What is the current status of trial NCT03450070?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2017-11-15. Estimated completion is 2017-12-22.
What conditions does trial NCT03450070 study?
This clinical trial studies the following conditions: Allergic Sensitization.
What interventions are being tested in trial NCT03450070?
The interventions under investigation include: Light Therapy Mask Cream (DEVICE).
Who is sponsoring clinical trial NCT03450070?
This trial is sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03450070 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03450070's enrollment target sits among peer trials
121 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI